BACKGROUND: Currently, the cosmetic industry is overwhelmed in keeping up with the safety assessment of the increasing number of new products entering the market. To meet such demand, research centers have explored alternative methods to animal testing and also the large number of volunteers necessary for preclinical and clinical tests. OBJECTIVES: This work describes the human skin ex-vivo model (hOSEC: Human Organotypic Skin Explant Culture) as an alternative to test the effectiveness of cosmetics and demonstrate its viability through cutaneous keratinocytes' proliferative capacity up to 75 days in culture. METHODS: The skin explants obtained from surgeries were cultured in CO2-humid incubator. After 1, 7, 30 and 75 days in culture, skin fragments were harvested for analysis with histomorphological exam (HE staining) on all days of follow-up and immunohistochemistry for Ck5/6, Ck10 and Ki-67 only on the 75th day. RESULTS: On the 7th day, the epidermis was perfect in the dermoepidermal junction, showing the viability of the model. On the 30th day, the epidermis was thicker, with fewer layers on the stratum corneum, although the cutaneous structure was unaltered. On the 75th day, the skin became thinner but the dermoepidermal junctions were preserved and epidermal proliferation was maintained. After the 75th day on culture, the skin was similar to normal skin, expressing keratinocytes with Ck5/6 on supra-basal layers; Ck10 on differentiated layers; and viability could be assessed by the positivity of basal cells by Ki-67. CONCLUSION: The hOSEC model seems a good alternative to animal testing; it can be used as a preclinical test analogous to clinical human skin test with similar effectiveness and viability proven by immunohistological analyses.
BACKGROUND: Currently, the cosmetic industry is overwhelmed in keeping up with the safety assessment of the increasing number of new products entering the market. To meet such demand, research centers have explored alternative methods to animal testing and also the large number of volunteers necessary for preclinical and clinical tests. OBJECTIVES: This work describes the human skin ex-vivo model (hOSEC: Human Organotypic Skin Explant Culture) as an alternative to test the effectiveness of cosmetics and demonstrate its viability through cutaneous keratinocytes' proliferative capacity up to 75 days in culture. METHODS: The skin explants obtained from surgeries were cultured in CO2-humid incubator. After 1, 7, 30 and 75 days in culture, skin fragments were harvested for analysis with histomorphological exam (HE staining) on all days of follow-up and immunohistochemistry for Ck5/6, Ck10 and Ki-67 only on the 75th day. RESULTS: On the 7th day, the epidermis was perfect in the dermoepidermal junction, showing the viability of the model. On the 30th day, the epidermis was thicker, with fewer layers on the stratum corneum, although the cutaneous structure was unaltered. On the 75th day, the skin became thinner but the dermoepidermal junctions were preserved and epidermal proliferation was maintained. After the 75th day on culture, the skin was similar to normal skin, expressing keratinocytes with Ck5/6 on supra-basal layers; Ck10 on differentiated layers; and viability could be assessed by the positivity of basal cells by Ki-67. CONCLUSION: The hOSEC model seems a good alternative to animal testing; it can be used as a preclinical test analogous to clinical human skin test with similar effectiveness and viability proven by immunohistological analyses.
Side effects caused by pharmaceutical and topical products are of increasing concern for
patients, dermatologists and the chemical industry. Chemicals may be hazardous to the
skin, inducing cutaneous irritation, burns and allergies. The regulatory guidelines, as
proposed by the European Union, require that data on the level of irritancy of new
chemicals must be reported.[1] In addition, the
irritancy potential of existing substances may need to be re-evaluated if current data
are judged to be insufficient. Development of new compounds requires their safety
assessment for humans and the environment.A large number of animals, especially rabbits, are still used to test the dermal
irritancy of chemical compounds.[2] For ethical
reasons, the use of experimental animals for skin irritation studies is not desirable,
especially to test cosmetic products. A number of alternative methods to test for skin
irritation have been proposed and several were evaluated at the ECVAM (European Centre
for the Validation of Alternative Methods) in pre-validation trials, but none has been
successfully pre-validated yet.[3] Some of these
methods are based on human keratinocyte culture to analyze the metabolism of
dimethyl-thiazoldiphenyltetrazolium bromide (MTT) by cellular lactate dehydrogenase
(LDH) connections or neutral red from preloaded cells[4]-[6] However, some
disadvantages must be considered, since these analyses have to be made in a short
timeframe and using only diluted products or chemicals in culture medium. Additionally,
there is no skin resurfacing in these models to permit topical products to be directly
applied, as occurs during in vivo testing.The hOSEC (human organotypic skin explant culture) represents a model that is closer to
in vivo human skin, like a 3D human skin model, consisting entirely
of melanocytes, Langerhans cells, keratinocytes, and the whole structure of dermal
fibroblasts, glycosaminoglycans and collagen, ideal for laboratory testing. Such
features became essential for its differentiation from the existing three-dimensional
validated models, which are composed only by keratinocytes and fibroblasts on a
devitalized extracellular matrix. By presenting an air-liquid interface, the hOSEC
system allows the application of creams, ointments and lipid-soluble substances on the
horny layer, whereas in a cell culture system it is possible to add substances that are
soluble in its medium due to the absence of a stratum corneum.[7]-[10]Considering the complete structure of hOSEC as human skin, this model seems appropriate
for testing of topical cutaneous products like sunscreen. Some authors have used the
hOSEC model to analyze cell migration into the skin after chemical sensitization; others
evaluate it through keratinocyte cytotoxicity by measuring the disappearance of
keratinocytic RNA, which is visualized using a modified methyl green-pyronine (MGP)
staining.[7]-[10] Although these studies have demonstrated the viability of this
model, in none of them was such viability longer than 3 weeks, and neither was the
explanted skin's proliferative capacity.So, the purpose of this study is to demonstrate the ex vivo model of
human skin (hOSEC) as an alternative for sunscreen (sun protection factor - SPF)
efficacy tests and demonstrate its viability through cutaneous keratinocytes'
proliferative capacity for up to 75 days in culture.
MATERIAL AND METHODS
Human organotypic skin explant culture (hOSEC)
Skin was obtained with the informed consent of patients undergoing either breast or
abdomen reduction surgery, in accordance with the ethical guidelines of the Research
Ethics Committee of the Clinics Hospital at Ribeirao Preto Medical School, University
of Sao Paulo (protocol number 1669/2014).The explants were cut (1.0 cm[2]) and cultured
on metal grids into standard 6-well plates in contact with culture medium at 37ºC in
5% CO2 humidified air (Figure 1).
The culture media consist of Dulbecco's Modified Eagle Medium (DMEM) with 10% Fetal
Bovine Serum (Sigma-Aldrich, Germany), 1% anti-anti (10.000 units penicillin, 10 mg
streptomycin and 25 µg amphotericin B - Sigma-Aldrich, Germany) and 1% L-glutamine
(Sigma-Aldrich, Germany). After 1, 7, 30 and 75 days in culture, the explants were
harvested, fixed in formalin, embedded in paraffin in compliance with histology and
immunohistochemistry methods.[10]
FIGURE 1
The explants were cut (1.0 cm2) and cultured on metal grids in
standard 6-well plates, in contact with culture medium at 37°C in 5%
CO2 humidified air
The explants were cut (1.0 cm2) and cultured on metal grids in
standard 6-well plates, in contact with culture medium at 37°C in 5%
CO2 humidified air
Histology
Paraffined sections (3.0 µm) were stained with hematoxylin eosin (HE) for
histomorphological analysis. Changes in epidermal morphology assessments were
followed by qualitative analysis using LEICA® DM-4000B optical
microscope with a LEICA® DFC 280 camera connected to the computer,
with LAS® - Leica Application for capturing images (Leica
Microsystems,Germany) software.
Immunohistochemistry
Three-micrometer paraffined sections were subjected to antigen retrieval by
autoclaving in citrate buffer, pH 6.0, for 5 minutes. Endogenous peroxidase was
blocked with 3% hydrogen peroxide in PBS, followed by nonspecific blocking with 1%
BSA. The sections were incubated with primary antibody in 1% BSA overnight at 4ºC.
The antibodies used were mouse anti-humanCk5/6 (1:100 dilution), Ck10 (1:100) and
Ki-67 (1:100) (Santa Cruz Biotechnology, USA). NovoLink Polymer Detection System Kit
(Novocastra Laboratories Ltd, Newcastle Upon Tyne, UK) was used. The color reaction
was developed by 3,3 diaminobenzidine tetrahydrochloride (Sigma-Aldrich, Germany).
The sections were counterstained with Mayer's hematoxylin and mounted in Entelan
(Sigma-Aldrich, Germany). The expression of Ck5/6 (basal cells of epidermis), Ck10
(stratum corneum) and Ki-67 (proliferative keratinocyte) were analyzed qualitatively
only on the 75th day of follow-up.
RESULTS
Histological evaluation
Histologically, the model showed viability on the 7th day, as the
appearance of the epidermis was similar to that of the 1st day and it
maintained a perfect connection on the dermoepidermal junction. Furthermore, on the
7th day, the epidermis presented all the strata: basal, spinosum,
granulosum and corneum. There were not any changes observed on the dermis. On the
30th day the epidermis was thicker and with less stratum spinosum,
although the cutaneous structure was unaltered and still viable to receive the
application of topical products. On the 75th day, the skin became thinner,
but the dermoepidermal junction was unchanged and there was proliferation of the
epidermis (Figure 2).
FIGURE 2
Hematoxylin eosin staining of skin on culture on days 1, 7, 30 and 75
proving the viability of hOSEC method by the proliferative capacity of
keratinocytes (magnification: 100x and 400x)
Hematoxylin eosin staining of skin on culture on days 1, 7, 30 and 75
proving the viability of hOSEC method by the proliferative capacity of
keratinocytes (magnification: 100x and 400x)
Immunohistochemical evaluation
After the 75th day on culture, the skin at immunohistochemical examination
was similar to normal skin, expressing keratinocytes with Ck5/6 on supra-basal
layers; Ck10 on upper differentiated layers and presenting viability which could be
confirmed by the positivity of basal cells to Ki-67. (Figure 3).
FIGURE 3
Immunohistochemical staining of skin on culture on day 75 for Ck5/6, Ck10
and Ki-67, proving the viability of hOSEC method by the proliferative capacity
of keratinocytes (magnification: 100x and 400x)
Immunohistochemical staining of skin on culture on day 75 for Ck5/6, Ck10
and Ki-67, proving the viability of hOSEC method by the proliferative capacity
of keratinocytes (magnification: 100x and 400x)
DISCUSSION
Animal testing for cosmetic products were banned in several countries and the industries
in this field suffered serious constraints[8].
Therefore, research centers are attempting to develop alternative methods to animal
use.The hOSEC is a system of human skin in culture medium, which is the closest to
in vivo condition because it maintains all skin structure such as
melanocytes, Langerhans cells, keratinocytes, and the entire structure of dermal
fibroblasts, glycosaminoglycans and collagen[8].
Due to these aspects it seems suitable to evaluate the safety and efficacy of topical
products such as sunscreens for example,[9] besides
retaining important elements of in vivo skin, showing significant
advantages for in vitro wound healing studies.[10] It was initially described in studies on allergic contact
dermatitis, lasting up to 3 weeks in culture.[9]The present study demonstrated cell viability/vitality of human skin fragments in
culture for 75 days. The hOSEC model's viability was confirmed by the maintenance of
dermoepidermal junctions and epidermal proliferation, according to histological and
immunohistochemical data for Ck5/6, Ck10 and the Ki-67 proliferation marker. Thus, this
method is feasible for cosmetic testing up to 75 days. Moreover, its implementation is
faster and less expensive than available in vitro systems.However, this model has some limitations, such as the lack of innervation and
circulation. Integration of blood vessels or the equivalent has been the subject of
extensive research.[11],[12]Communication in the skin is mediated by cytokines, neurotransmitters, hormones, growth
factors and eicosanoids, which can be added to the culture medium although cell-to-cell
interactions also appear to be necessary.[8]The presence of all epidermal and dermal cellular types, immune cells such lymphocytes,
dendritic cells, macrophages, and the conservation of the in vivo
structure and physiology has permitted the use of skin explant in a large panel of
diseases and processes, including immune diseases, wound healing, extracellular matrix
process, ageing, cancer and cosmetic tests. Furthermore, it represents a good tool to
understand physiopathology, and the lack of contact with the organism may be compensated
by the addition of many substances. It remains the most representative in
vitro model of human skin.[8]
CONCLUSION
The hOSEC model seems a good animal alternative method for safety assessment of cosmetic
products for human uses. In addition, it can be regarded as being valid for a
pre-clinical test similar to in vivo clinical human skin test because of the maintanance
of its viability which was confirmed by immunohistological analysis.
Authors: J H Fentem; D Briggs; C Chesné; G R Elliott; J W Harbell; J R Heylings; P Portes; R Roguet; J J van de Sandt; P A Botham Journal: Toxicol In Vitro Date: 2001-02 Impact factor: 3.500
Authors: Wei Xu; Seok Jong Hong; Shengxian Jia; Yanan Zhao; Robert D Galiano; Thomas A Mustoe Journal: Lab Invest Date: 2012-01-09 Impact factor: 5.662
Authors: Maria Ponec; Abdoelwaheb El Ghalbzouri; Remco Dijkman; Johanna Kempenaar; Gabri van der Pluijm; Pieter Koolwijk Journal: Angiogenesis Date: 2005-05-09 Impact factor: 9.596
Authors: J Demetrulias; T Donnelly; V Morhenn; B Jessee; S Hainsworth; P Casterton; L Bernhofer; K Martin; D Decker Journal: Exp Dermatol Date: 1998-02 Impact factor: 3.960
Authors: Leyla A Akh; Mohammad O Ishak; Jennifer F Harris; Trevor G Glaros; Zachary J Sasiene; Phillip M Mach; Laura M Lilley; Ethan M McBride Journal: Cell Mol Life Sci Date: 2022-07-01 Impact factor: 9.207
Authors: Alexandra C Kendall; Magdalena Kiezel-Tsugunova; Luke C Brownbridge; John L Harwood; Anna Nicolaou Journal: Biochim Biophys Acta Biomembr Date: 2017-03-21 Impact factor: 3.747
Authors: Béatrice M F Winkel; Mirjam R Dalenberg; Clarize M de Korne; Carola Feijt; Marijke C C Langenberg; Leonard Pelgrom; Munisha S Ganesh; Maria Yazdanbakhsh; Hermelijn Helene Smits; Esther C de Jong; Bart Everts; Fijs W B van Leeuwen; Cornelis H Hokke; Meta Roestenberg Journal: Front Immunol Date: 2018-10-31 Impact factor: 7.561